Titan Biotech Ltd
BSE:TITANBIOConsolidated figures
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross margin % | 54.6% | 51% | 51.5% | 53.9% | 53.6% | 53.3% |
Consolidated figures
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross margin % | 54.6% | 51% | 51.5% | 53.9% | 53.6% | 53.3% |
| EBITDA margin % | 32.4% | 26.8% | 20.5% | 20.9% | 16.3% | 18.7% |
| EBIT margin % | 30.9% | 25.2% | 18.7% | 18.9% | 13.6% | 16.3% |
| PAT margin % | 22.3% | 18.8% | 17.3% | 15.2% | 13.8% | 14.5% |
| Working capital | ||||||
| Receivable days | 46 | 52 | 53 | 42 | 44 | 40 |
| Inventory days | 184 | 206 | 189 | 220 | 255 | 212 |
| Payable days | 21 | 37 | 0 | 0 | 0 | 32 |
| NWC days | 209 | 221 | 242 | 262 | 299 | 220 |
| Leverage | ||||||
| Current ratio | 3.05 | 3.62 | 3.36 | 3.71 | 4.46 | 3.28 |
| Debt to EBITDA | 0.29 | 0.39 | 0.24 | 0.21 | 0.08 | 0.1 |
| Debt to equity | 0.19 | 0.16 | 0.06 | 0.05 | 0.01 | 0.02 |
| Interest coverage | 26.8 | 30.8 | 38.5 | 27.9 | 31.5 | 42.9 |
| Asset turnover | 1.41 | 1.07 | 1.07 | 1.04 | 0.9 | 0.96 |
| Return ratios | ||||||
| Return on assets % | 31.5% | 20% | 18.5% | 15.8% | 12.3% | 14% |
| Return on capital employed % | 54.9% | 39.6% | 24.8% | 26% | 17.1% | 22.7% |
| Return on equity % | 46.1% | 29.1% | 22.6% | 18.6% | 14% | 16.5% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.